Medtronic (NYSE:MDT) announced today that it received CE Mark approval in Europe for its MiniMed 780G next-generation insulin pump.
The closed-loop insulin pump system is indicated for treating Type 1 diabetes in people aged 7 to 80 years old. It uses Medtronic’s SmartGuard algorithm to automate the delivery of basal insulin and correction boluses every five minutes.
The MiniMed 780G enables the personalization of glucose goals with an adjustable target setting as low as 100 mg/dL, which is lower than any other advanced hybrid closed-loop system, according to a news release.
Medtronic said patients who participated in a clinical study said the MiniMed 780G system “made life with diabetes and control so much easier.” Results from three trials using the system will be presented in a symposium at the virtual 80th Scientific Sessions of the American Diabetes Association.
The company expects to begin shipping the MiniMed 780G system to select European countries in the coming fall. As of right now, it is available for investigational use only in the U.S.
“We wanted to design a system that further simplifies diabetes management and adapts to people’s life with the goal of enhancing their experience in a seamless way,” Medtronic executive VP & president of the diabetes group Sean Salmon said in the news release. “We know it can be challenging to have to calculate carbohydrate intake before every snack or meal on a daily basis to ensure the right amount of insulin is dosed. With this system, users will have an extra layer of coverage for those times they miscalculate their carbs or forget to pre-bolus with an algorithm that automatically corrects for high glucose when needed.
“We want to help people spend more time living their life and less time worrying about their diabetes management — we’re confident this system delivers on that important goal.”
